Efficacy of type-2 targeted biologics in patients with asthma and bronchiectasis

Bronchiectasis is characterized by permanent, irreversible dilation of the bronchi due to inflammation and impaired mucus clearance and is associated with significant respiratory impairment. Bronchiectasis shares significant clinical characteristics with severe asthma, and they often coexist.1 Although classically thought of as neutrophilic-predominant inflammation, emerging evidence suggests that the inflammation in bronchiectasis is heterogeneous with a subset of patients having an eosinophil-predominant type 2 inflammatory response.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research